Cantor Fitzgerald came away from last week’s conference with reinforced conviction on Gossamer Bio (GOSS), telling investors in a research note that sentiment is clearly improving ahead of the February 2026 PROSERA readout. The firm, which has an Overweight rating on Gossamer Bio shares, says the market is still mis-pricing seralutinib’s odds, even with the recent stock run-up.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio upgraded to Buy from Neutral at UBS
- Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts
- Gossamer Bio Reports Q2 2025 Financial Results
- Gossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating
- Gossamer Bio reports Q2 EPS (17c) , consensus (18c)